References
- European Antimicrobial Resistance Surveillance Network (EARS-Net). http://ecdc.europa.eu/en/healthtopics/antimicrobial_resistance/database/Pages/database.aspx. Accessed, August 25, 2016.
- Pitout JDD, Nordmann P, Poirel L. Carbapenemase-Producing Klebsiella pneumoniae, a Key Pathogen Set for Global Nosocomial Dominance. Antimicrob Agents Chemother 2015; 59:5873-84; PMID:26169401; http://dx.doi.org/10.1128/AAC.01019-15
- Petrosillo N, Giannella M, Lewis R, Viale P. Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art. Expert Rev Anti Infect Ther 2013; 11:159-77; PMID:23409822; http://dx.doi.org/10.1586/eri.12.162
- De Rosa FG, Corcione S, Cavallo R, Di Perri G, Bassetti M. Critical issues for Klebsiella pneumoniae KPC-carbapenemase producing K. pneumoniae infections: a critical agenda. Future Microbiol 2015; 10:283-94; PMID:25689539; http://dx.doi.org/10.2217/fmb.14.121
- Rafailidis PI, Falagas ME. Options for treating carbapenem-resistant Enterobacteriaceae. Curr Opin Infect Dis 2014; 27:479-83; PMID:25259809; http://dx.doi.org/10.1097/QCO.0000000000000109
- Wiskirchen DE, Crandon JL, Nicolau DP. Impact of various conditions on the efficacy of dual carbapenem therapy against KPC-producing Klebsiella pneumoniae. Int J Antimicrob Agents 2013; 41:582-5; PMID:23611306; http://dx.doi.org/10.1016/j.ijantimicag.2013.02.015
- Daikos GL, Markogiannakis A. Carbapenemase-producing Klebsiella pneumoniae:(when) might we still consider treating with carbapenems? Clin Microbiol Infect 2011; 17:1135-41; PMID:21635663; http://dx.doi.org/10.1111/j.1469-0691.2011.03553.x
- Tumbarello M, Trecarichi EM, De Rosa FG, Giannella M, Giacobbe DR, Bassetti M, Losito AR, Bartoletti M, Del Bono V, Corcione S, et al. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother 2015; 70:2133-43; PMID:25900159; http://dx.doi.org/10.1093/jac/dkv200
- Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, Spanu T, Ambretti S, Ginocchio F, Cristini F, et al. Predictors of Mortality in Bloodstream Infections Caused by Klebsiella pneumoniae Carbapenemase–Producing K. pneumoniae: Importance of Combination Therapy. Clin Infect Dis 2012; 55:943-50; PMID:22752516; http://dx.doi.org/10.1093/cid/cis588
- Qureshi ZA, Paterson DL, Potoski BA, Kilayko MC, Sandovsky G, Sordillo E, Polsky B, Adams-Haduch JM, Doi Y. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 2012; 56:2108-13; PMID:22252816; http://dx.doi.org/10.1128/AAC.06268-11
- Del Bono V, Giacobbe DR, Marchese A, Parisini A, Fucile C, Coppo E, Marina ML, Arena A, Molin A, Martelli A, et al. Meropenem for treating KPC-producing Klebsiella pneumoniae bloodstream infection: should we get to the root of the PK/PD paradox? Virulence 2017; 8(1):66-73; http://dx.doi.org/10.1080/21505594.2016
- Drusano GL. Antimicrobial pharmacodynamics: critical interactions of bug and drug'. Nat Rev Microbiol 2004; 2(4):289-300; PMID:15031728
- Chou T-C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58:621-81; PMID:16968952; http://dx.doi.org/10.1124/pr.58.3.10